Analyst firms · Piper Sandler · CTMX
Piper Sandler CTMX price target and rating history
CytomX Therapeutics Inc. (CTMX) · Health Care
Piper Sandler rates CytomX Therapeutics Inc. (CTMX) Overweight with a $2.50 price target, as of its latest action on Apr 14, 2025. It has published 3 rating actions on CTMX since July 2022, including 1 upgrade and 1 downgrade.
- Current rating
- Overweight
- Price target
- $2.50
- Median target, all firms
- Too few
- Actions on CTMX
- 3
Piper Sandler price target on CTMX
Every Piper Sandler rating on CTMX
- Apr 14, 2025
- May 28, 2024
- Jul 7, 2022
How other firms rate CTMX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $6 | May 19, 2026 |
| Guggenheim | Buy | $10 | Jan 20, 2026 |
Questions about Piper Sandler and CTMX
- What is Piper Sandler's price target for CTMX?
- Piper Sandler's latest stated price target for CytomX Therapeutics Inc. (CTMX) is $2.50, from its action on Apr 14, 2025.
- What is Piper Sandler's rating on CTMX?
- Piper Sandler rates CTMX Overweight, a bullish rating, as of Apr 14, 2025.
- When did Piper Sandler last change its view on CTMX?
- On Apr 14, 2025, Piper Sandler resumes coverage at Overweight, price target $3.25 to $2.50.
All Piper Sandler ratingsCTMX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.